Phase 2 N=21 NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
Severe Aplastic Anemia · Aplastic Anemia · Bone Marrow Failure
Primary: Overall Survival and Engraftment at One Year — 19 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
Severe Aplastic Anemia
Primary: Percentage of Participants With Overall Survival (OS) — 80.6 percentage of participants
N/A N=187 The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
Acute Migraine
Primary: Proportion of Subjects Reporting Reduction of Migraine Headache Pain at 2 Hours From Treatment Initiation — 30; 22 Participants — p=0.018
Phase 3 N=374 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD)
Primary: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score…
Phase 3 N=21 A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
Primary Hyperoxaluria Type 1 · Primary Hyperoxaluria
Primary: Cohort A: Percent Change in Plasma Oxalate From Baseline to Month 6 — -33.33 percent change
Phase 1 N=30 A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 2; 2; 9; 12 Participants
Phase 1 N=60 This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down Midazolam
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events — 20.0; 50.0; 12.5; 0.0 Percentage of participants (%)
Phase 4 N=44 An Analysis of the Efficacy of a Pre-Emptive Multimodal Pain Regimen in Reducing Acute Post-Operative Pain and Narcotic Pain Medication Requirements in Spine Surgery
Pain, Postoperative · Spine Injuries and Disorders · Narcotic Use
Primary: Visual Analogue Scale (VAS) for Pain — 4.8 score on a scale
Phase 1 N=27 Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 5; 6; 6; 7 Participants
N/A N=82 Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region
Lax Skin
Primary: Day 180 Number of Participants With Improvement Measured By Independent Photographic Review — 6; 52 Participants — p=<0.0001
N/A N=33 A Digital Intervention to Prevent Initiation of Opioid Misuse in Adolescents in School-based Health Centers
Opioid Misuse
Primary: Knowledge Questions — 100 Percentage of Questions Correct
Phase 2 N=42 Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
B-cell Lymphoma
Primary: Complete Response (CR) Rate Per the Lugano Classification as Determined by Study Investigators — 86 percentage of participants
Phase 2 N=27 Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
Glomerulonephritis
Primary: Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) — 0.55 ratio — p=0.0003
Phase 3 N=460 A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
Gastric Cancer · Gastric Adenocarcinoma
Primary: Overall Survival (OS) — 5.82; 5.13 Months
Phase 2 N=59 An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
Prostate Cancer · Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Primary: Percentage of Participants With Confirmed Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 5; 0 Percentage of participants